BeiGene Ltd (BGNE) Received its Third Buy in a Row


After Maxim Group and Piper Jaffray gave BeiGene Ltd (NASDAQ: BGNE) a Buy rating last month, the company received another Buy, this time from Cowen & Co. Analyst Yaron Werber maintained a Buy rating on BeiGene Ltd today and set a price target of $170. The company’s shares opened today at $121.38.

According to TipRanks.com, Werber is a 5-star analyst with an average return of 13.0% and a 63.6% success rate. Werber covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Inc., Rocket Pharmaceuticals Inc, and Unum Therapeutics Inc.

Currently, the analyst consensus on BeiGene Ltd is a Strong Buy with an average price target of $170, implying a 40.1% upside from current levels. In a report issued on June 13, CLSA also reiterated a Buy rating on the stock.

See today’s analyst top recommended stocks >>

The company has a one-year high of $194.56 and a one-year low of $105.19. Currently, BeiGene Ltd has an average volume of 305.4K.

Based on the recent corporate insider activity of 47 insiders, corporate insider sentiment is positive on the stock. This means that over the past quarter there has been an increase of insiders buying their shares of BGNE in relation to earlier this year.

TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.

BeiGene Ltd. is a commercial-stage biopharmaceutical company, which engages in the development and commercialization of innovative molecularly targeted and immuno-oncology drugs for the treatment of cancer. It focuses on Zanubrutinib (BGB-3111), Tislelizumab (BGB-A317), and Pamiparib (BGB-290).

Stay Ahead of Everyone Else

Get The Latest Stock News Alerts